Ann: Positive IHL-675A in vivo results and FDA Pathway, page-70

The FDA is not against HCQ.

How many times does this piece of misinformation need to be addressed. HCQ is an off label drug which can be prescribed right now as I type by a Doctor. It’s been FDA approved for decades, and continues to be prescribed legally and safely.

That said, the synergistic response of HCQ and CBD in IHL-675A will likely result in lower doses of HCQ being administered. And ultimately drug development is all about efficacy at the safest dose possible.

Excellent results today and from my perspective this lowers the investment risk for IHL-675A substantially. As @Chaya inferred, this is the point of consolidation at higher and higher prices until we get the catalyst that drives the stock potentially multiples of current value. Let’s call it the ADN moment!

And there are many near term catalysts ahead.